Drugs / GIB-7
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07363057 | Jan → May 2026 overdue | — | GI Innovation, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-05-13 | GI Innovation, Inc. | [보도자료]지아이이노베이션-지아이바이옴, ‘엑스프라이즈 헬스스팬’ 준결승 진출...GI-102·GIB-7 병용요법으로 항노화 가능성 입증 gi-innovation.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GIB-7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07363057 ↗ |
| Modality | Other / unclassified | “GIB-7: synbiotic formula” NCT07363057 ↗ |
| Route | Oral | “GIB-7: synbiotic formula, oral administration” NCT07363057 ↗ |